25 results
424B2
SAVA
Cassava Sciences Inc
3 Jan 24
Prospectus for primary offering
4:22pm
or price transparency or may have an unusually high bid-ask spread. You may be unable to sell your Warrants at a price that is favorable to you
CORRESP
SAVA
Cassava Sciences Inc
10 Aug 23
Correspondence with SEC
12:00am
or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense
UPLOAD
SAVA
Cassava Sciences Inc
28 Jul 23
Letter from SEC
12:00am
and
development costs by project. Provide other quantitative or
qualitative disclosure that
provides more transparency
8-K
EX-99.1
SAVA
Cassava Sciences Inc
26 Apr 22
Regulation FD Disclosure
3:45pm
exempted from similar standards of transparency and full disclosure. That would have been useful information for readers of The New York Times … stalling a promising drug treatment for people with Alzheimer’s. All the more reason why transparency and disclosure are paramount.
The reporter’s use
8-K
EX-99.1
5z4oa
8 Feb 19
Pain Therapeutics Announces Feedback from
4:04pm